Dennis Henner, PhD, has been Managing Director of Clarus Ventures since the firm’s inception in 2005. He has over 27 years of direct industry and investment experience within the healthcare sector, including being a General Partner in a healthcare venture capital firm since 2001. From 1981 to 2001, Dr. Henner was an executive at Genentech (NYSE:DNA) where he held various positions including Senior Vice President of Research, and member of Genentech’s executive committee.
Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Dr. Henner represents Clarus Ventures on the Board of Directors of CoMentis, Ferrokin, Pelikan Technologies, ProActa, and SARcode. In addition he is on the Board of Directors of Ceregene, and Kalobios.
Previous directorships include,Cellerant, Rinat (acquired by Pfizer), Synergia, and Tercica (spinout from Genentech; NASDAQ:TRCA).
